UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
August 7, 2025
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻
Furnished as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the “Company”) for the three and six-month periods ended June 30, 2025, and furnished as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated August 7, 2025, announcing the Company’s results for the three and six-month periods ended June 30, 2025.
On August 7, 2025, the Company issued a press release titled, “ProQR Announces Second Quarter 2025 Operating and Financial Results,” announcing the Company’s results for the three and six-month periods ended June 30, 2025 and providing a business update. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
ProQR hereby incorporates by reference the information contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File No. 333-263166 and File No. 333-285767).
INDEX TO EXHIBITS
| | |
Number | | Description |
| | |
99.1 | | Unaudited financial statements of ProQR Therapeutics N.V. for the three and six-month periods ended June 30, 2025. |
| | |
99.2 | | Press Release of ProQR Therapeutics N.V. dated August 7, 2025, announcing the Company’s results for the three and six-month periods ended June 30, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| PROQR THERAPEUTICS N.V. |
| | |
| | |
Date: August 7, 2025 | By: | /s/ Dennis Hom |
| | Dennis Hom |
| | Chief Financial Officer |
